首页|Probiotics intervention in colorectal cancer:From traditional approaches to novel strategies

Probiotics intervention in colorectal cancer:From traditional approaches to novel strategies

扫码查看
原文链接
  • 国家科技期刊平台
  • NETL
  • NSTL
  • 万方数据
The intestine harbors a large population of microorganisms that interact with epithelial cells to maintain host healthy physiolog-ical status.These intestinal microbiota engage in the fermentation of non-digestible nutrients and produce beneficial metabolites to regulate host homeostasis,metabolism,and immune response.The disruption of microbiota,known as dysbiosis,has been implicated in many intestinal diseases,including colorectal cancer(CRC).As the third most common cancer and the second leading cause of cancer-related death worldwide,CRC poses a significant health burden.There is an urgent need for novel interventions to reduce CRC incidence and improve clinical outcomes.Modulating the intestinal microbiota has emerged as a promising approach for CRC prevention and treatment.Current research efforts in CRC probiotics primarily focus on reducing the incidence of CRC,alleviating treatment-related side effects,and potentiating the efficacy of anticancer therapy,which is the key to successful translation to clinical practice.This paper aims to review the traditional probiotics and new interventions,such as next-generation probiotics and postbiotics,in the context of CRC.The underlying mechanisms of probiotic anti-cancer effects are also discussed,including the restoration of microbial composition,reinforcement of gut barrier integrity,induction of cancer cell apoptosis,inactivation of carcinogens,and modulation of host immune response.This paper further evaluates the novel strategy of probiotics as an adjuvant therapy in boosting the efficacy of chemotherapy and immunotherapy.Despite all the promising findings presented in studies,the evaluation of potential risks,optimization of delivery methods,and consideration of intra-patient variability of gut microbial baseline must be thoroughly interpreted before bench-to-bedside translation.

colorectal cancerprobioticsgut microbiotadysbiosisadjuvant therapyimmune modulationgut barrrier

Suki Ha、Xiang Zhang、Jun Yu

展开 >

Institute of Digestive Disease and Department of Medicine and Therapeutics,State Key Laboratory of Digestive Disease,Li Ka Shing Institute of Health Sciences,The Chinese University of Hong Kong,Hong Kong SAR,China

National Key R&D Program of ChinaRGC Research Impact Fund Hong KongRGC Themebased Research Scheme Hong KongResearch Talent Hub(RTH)-ITF Scheme Hong Kong

2020YFA0509200/2020YFA0509203R4632-21FT21-705/20-NITS/177/21FP

2024

10.1097/CM9.0000000000002955

中华医学杂志(英文版)
中华医学会

中华医学杂志(英文版)

CSTPCD
影响因子：0.838
ISSN：0366-6999
年,卷(期)：2024.137(1)
  • 78